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Short title: Effects of T2T on body composition and function in RA 
 
Abstract  
Objective.  RA typically features “rheumatoid cachexia” (loss of muscle mass (MM) and excessive 
fat mass (FM), especially trunk FM), which contributes to physical disability.  Since rheumatoid 
cachexia is driven by inflammation, it would be anticipated that the success of tight control of 






























































disease activity, such as “treat-to-target” (T2T), in attenuating inflammation would benefit body 
composition and physical function.  This cross-sectional study assessed the impact of T2T on body 
composition and objectively-assessed function in RA patients. 
Methods.  Eighty-two RA patients exclusively treated by T2T, were compared to 85 matched 
sedentary healthy controls (HC).  Body composition was estimated by DXA, with appendicular lean 
mass (ALM) the surrogate measure of total MM.  Physical function was assessed by knee extensor 
strength, handgrip strength, 30s sit-to-stands, 8’ up & go, and 50’ walk (tests which reflect the ability 
to perform ADLs). 
Results.  Although generally well treated (mean DAS28=2.8, with 49 % in ‘remission’), RA patients 
had ~10% proportionally less ALM and were considerably fatter (by ~27%), particularly in the trunk 
(~32%), than HC’s.  All measures of function were 24-34% poorer in the RA patients relative to HC. 
Conclusion.  Despite marked improvements in disease control (most patients achieving or 
approaching ‘remission’), the relative loss of MM and increased adiposity in RA patients compared 
to matched-HC is similar to that observed pre-T2T. Additionally, performance of objective function 
tests is unchanged from that reported by our group for pre-T2T RA patients.  Thus T2T, even in 
responsive RA patients, has not attenuated rheumatoid cachexia or improved objectively-assessed 
function. 




• T2T RA patients still show significant muscle loss, exacerbated adiposity and 
substantially impaired physical function. 






























































• Patients responding to T2T typically have the physical function of healthy individuals 
25 years older. 
• By concentrating on DAS28, T2T protocols may distract rheumatologists’ attention 
from physical function.  
 
INTRODUCTION 
Rheumatoid arthritis (RA) is characterised by adverse changes in body composition (i.e. reduced 
muscle mass and increased adiposity) termed ‘rheumatoid cachexia’ [1].  Although prevalence of this 
condition varies according to measurement method and definition employed, muscle loss of 7.4-
14.0% relative to matched healthy controls [2-5] are observed in up to 67% of stable RA patients [3, 
6-15] whilst obesity, determined by body composition, is present in up to 80% of stable patients [3, 
9-12, 16], with trunk adiposity especially prevalent [3, 8, 9-12, 17-18].  These changes in body 
composition, as well as exacerbating mortality and co-morbidity risk [15-19], also contribute 
significantly to disability [7, 20-22]. 
In recent years, individually tailored treatment strategies featuring early and aggressive DMARD use 
and frequent monitoring of treatment response to achieve low disease activity (LDA), preferably 
‘clinical remission’, have been the cornerstone of pharmacologic treatment of RA.  This approach, 
best exemplified by ‘treat-to-target’ (T2T) [23-24], has been shown to be substantially more effective 
in controlling inflammation and arresting progression of joint damage than previous treatment 
regimens [23-26]. Given that rheumatoid cachexia is thought to be driven by DA, and inflammation 
in particular [3, 14-15, 27], it would be anticipated that the tighter control of DA/inflammation 
achieved by T2T would attenuate rheumatoid cachexia and, as a consequence, reduce functional 
limitations in RA patients.  Pertinently, restoration of functional ability is an explicit aim of both 
EULAR and ACR recommendations for T2T [23-24, 28].  Although studies assessing body 
composition in RA patients have been performed since the widespread use of T2T (~2008), these 






























































studies [4, 6, 8, 10, 18, 20, 29-31] have either exclusively or primarily used patients who commenced 
treatment years prior to the adoption of T2T, and therefore do not inform on the effects on body 
composition of T2T per se.  Additionally, investigations into the impact of T2T on physical function 
have, to date, only used subjective instruments such as the Health Assessment Questionnaire (HAQ) 
[26, 32-33].  However, these measures are strongly influenced by pain [34-35], which diminishes 
with T2T, and are often insensitive to changes in function in patients with controlled disease [9, 36]. 
Thus, we aimed to determine whether the adverse effects of RA on body composition and physical 
function still exist in this era of tight control of DA.  To this end, we compared body composition 
and objectively-assessed physical function of RA patients exclusively treated by T2T era with that of 
age- and sex-matched healthy sedentary controls (HC).  Additionally, we compared our current 
findings with those previously reported by our group for stable RA patients (i.e. studies performed 
either before local adoption of T2T strategies, or, if more recent, on patients who commenced 
treatment pre-T2T [3-4, 9-12, 30]).  Lastly, this investigation sought to further examine the time-
courses of rheumatoid cachexia and RA disability.  
 
METHODS  
This cross-sectional study was conducted between February 2013 and March 2015, in compliance 
with the Helsinki Declaration, and with approval from the North Wales Research Ethics Committee 
– West (12/WA/0323). 
 
Study population 
RA patients with stable disease were recruited from outpatient clinics of the Peter Maddison 
Rheumatology Centre (PMRC), North Wales. For inclusion, participants had to: (a) fulfil the ACR 
2010 revised criteria for RA [37]; (b) be aged ≥ 18 years; (c) not be cognitively impaired; (d) be free 
of other cachectic diseases or conditions preventing safe participation; (e) not be taking anabolic 






























































drugs or nutritional supplements; and (f) not be pregnant. Only patients who commenced DMARD 
treatment following the PMRC’s adoption of treatment strategies in-line with the T2T 
recommendations of Smolen et al [23] (i.e. post 1/1/2008) were included.  Once recruited, 
participants were categorised into either ‘recent-onset’ (≤ 12 months since diagnosis) or ‘established’ 
(> 12 months since diagnosis) disease cohorts.  
 
For comparison, sedentary age- and sex-matched HC were recruited from the local community. To 
be eligible for the study, HC must have satisfied all of the inclusion criteria for RA patients, except 
for the diagnosis of RA. 
 
Assessments and outcome measures 
Participants presented for assessments in an overnight fasted state.  
 
Anthropometric and body composition measures 
Routine anthropometric measures (body mass (BM), height, and waist and hip circumferences) were 
performed using standard procedures. 
 
Total and regional lean, fat, and bone masses were estimated using a whole body fan-beam DXA 
scanner (Hologic, QDR Discovery 45615, software V12.4), with appendicular lean mass (ALM) 
used as a surrogate measure of total body muscle mass [3].  The in-house co-efficient of variation 
(CV) of 1.4% of our scanner complies with manufacturer’s guidelines. 
 
Objective physical function 
Maximal isometric knee extensor strength (IKES) was measured using an isokinetic dynamometer 
(Humac Cybex Norm 2004, Computer Sports Medicine Inc., Massachusetts, USA) and maximal 






























































handgrip strength (HGS) by a Grip-A dynamometer (Takei Kiki Kogyo, Japan) using previously 
described protocols [3]. Three objective function tests, specifically developed to evaluate the 
capacity of older adults to perform activities of daily living (ADL [38]): ‘sit-to-stands in 30 seconds’ 
(STS-30), ‘8-foot up and go’ (8’UG) and ‘50-foot walk’ (50’W) tests), were also performed. Before 
each of the strength and function tests, which are routinely used by our group [3-4, 9-12, 30-31, 39], 
participants had a submaximal practice.  
 
Clinical measures. Disease activity was assessed by the Disease Activity Score in 28 joints (DAS28) 
using C-reactive protein (CRP), with ‘remission’ defined as DAS28 < 2.6.  Physical disability was 
subjectively evaluated by the Multidimensional Health Assessment Questionnaire (MDHAQ [40]).   
 
Statistical analysis 
The primary outcome of the study was ALM normalised for BM (ALM %), as this is the LM 
measure most relevant to performing ADL (i.e. comparing absolute ALM ignores disparities in BM 
and the effect fat mass (FM) has on performing ADL). The secondary outcomes included other 
aspects of body composition (total LM, total FM, trunk FM, and % body fat (BF%)) and the 
objective physical function measures. 
 
The primary statistical analyses involved comparison of the RA group versus the HC group, 
followed by sub-analyses of: ‘recent-onset’ versus ‘established’ RA patients; RA patients who, at the 
time of testing, had achieved clinical remission versus patients who had not; ‘remission’ patients 
versus HC; and finally, informal comparison of current results with our ‘historic’, pre-T2T data [3-4, 
9-12, 30-31; patients for these studies generally commenced treatment 1992-2004]. Statistical 
analysis involved multiple (MANOVA) or univariate analysis of variance (ANOVA) according to 
appropriateness, and Chi-squared tests were used for comparison of dichotomous variables. 


































































One hundred and ninety-seven (n = 197) patients with RA were deemed eligible for the study and 
approached. Of these, 115 (58%) declined participation (primarily due to: ‘not interested’ or time 
and/or travel constraints) leaving 82 patients who were recruited.  At the time of assessment, 33 of 
these 82 patients had been diagnosed ≤ 12 months previously (‘recent-onset’ group; mean disease 
duration ~7 months), whilst the remaining 49 had a disease duration of 1-7 years (‘established’ 
group; mean duration ~2 years 11 months). Eighty-five age- and sex-matched sedentary HC 
participants were also recruited. 
 
Demographic and clinical characteristics 
Table 1 displays the demographic and clinical characteristics of the 82 RA patients and 85 HC 
participants. These groups were precisely matched for mean age (P = 0.962) and gender distribution 
(P = 0.992). RA patients were more frequently current (P < 0.001) or former (P < 0.001) smokers, 
and generally were more sedentary (P < 0.001) than the HC. With regard to DA, the mean DAS28 
score was 2.8, indicating generally ‘low DA’, and 49% of patients had achieved a current state of 
‘clinical remission’. DMARD treatment is summarised in Table 1. 
 
No differences in demographic or clinical characteristics were identified between the ‘recent-onset’ 
or ‘established’ RA patients (data not shown), with the exception of disease duration and the 
proportion on combination therapy (7.1 ± 3.0 vs 34.7 ± 17.0 months, P < 0.001; and 16/33 (48%) vs 
14/49 (29%), P = 0.066, respectively). 
 






























































Anthropometry and body composition  
Anthropometric and DXA-assessed body composition data appear in Table 2.  Despite being shorter 
(mean ~3cm, P = 0.019), RA patients were heavier (mean BM: +4.8 kg, P = 0.093), and 
consequently their mean BMI higher (P = 0.002), than the HC. RA patients also had a greater mean 
waist circumference (+7.7 cm, P = 0.001) and waist:hip ratio (P < 0.001) than HC. 
  
When adjusted for BM (i.e. % of), RA patients had ~10% less muscle than HC (ALM %, P < 0.001).  
This relative deficit corresponds with the proportional loss of ALM we observed in stable RA 
patients, of similar age and gender distribution, who had commenced treatment ~1992-2004 (i.e. 
~9%, RA n = 23, matched HC, n = 23 [4]; ~11%, RA n = 20, matched HC, n = 20 [3]).  When 
expressed absolutely (kg), RA patients in the current study exhibited less ALM (-1.1 kg) and TLM (-
0.8 kg) than the HC, although these differences were not statistically significant. 
 
DXA-assessed body composition confirmed that RA patients were considerably fatter than HC, with 
the group differences in BM more than accounted for by higher total FM in patients (+5.4 kg, 26.5% 
greater, P < 0.001).  Consequently, BF% was also higher in patients (P < 0.001).  As anticipated, the 
majority of this increased adiposity was situated on the trunk (+3.2 kg, 32.3% higher than HC, P = 
0.001). In pre-T2T patients we had noted mean increases in total FM of ~17% [4] and ~13% [3] 
relative to HC. 
 
No differences in anthropometric or DXA measures were evident between the ‘recent-onset’ and 
‘established’ RA patients (data not shown; P’s = 0.654 - 0.998). 
 
Objective physical function 






























































Compared with HC, RA patients performed poorly in each of the objective function measures (Table 
3): IKES was 24.3% less (P < 0.001); HGS, 25.3% less (P < 0.001); STS-30, 34.2% less (P < 0.001); 
8’UG, 31.1% slower (P < 0.001); and 50’W, 28.0% slower (P < 0.001). The absolute levels of 
performance for those tests not subject to equipment changes (i.e. STS-30, 8’UG, 50’ W), achieved 
by RA patients in the current study are similar to those we observed in stable pre-T2T RA patients 
(STS-30: mean range 10.9 – 14.7 repetitions, overall mean = 12.4 (vs 12.0 repetitions in the current 
study) [3-4, 9-12, 30-31]; 8’UG: mean range 6.0 – 6.4 secs, overall mean = 6.2 (vs 7.4 secs) [4, 30-
31]; 50’W mean range 9.1 – 10.0 secs, overall mean = 9.5 (vs 10.7 secs) [4, 9-10, 30-31]. 
 
As with the anthropometric and body composition measures, there were no differences in 
performance for any of the objective function tests between the ‘recent-onset’ and ‘established’ RA 
patients (data not shown; P’s = 0.435 - 0.778). 
 
Subjective measures of disability and health 
As expected, RA patients had higher MDHAQ scores than the HC group (P = 0.001; Table 1). 
Despite the marked impairments in objectively-assessed physical function relative to HC, the RA 
patients subjectively regarded themselves as only ‘mildly disabled’ (Table 1). There was no 
difference in MDHAQ scores between ‘recent-onset’ and ‘established’ RA patients (data not shown, 
P = 0.880). 
 
‘Remission’ versus ‘non-remission’ RA patients 
Of the 82 RA patients, 40 had achieved clinical remission at the time of assessment (DAS28: 2.0 ± 
0.4).  There were no differences in age, seropositivity, disease duration or medication between 
‘remission’ and ‘non-remission’ patients, however, proportionally fewer females achieved 
‘remission’ (58% vs 71%, P = 0.187) (Table 4). 































































In comparison to those not in remission (DAS28: 3.6 ± 0.8), the ‘remission’ patients generally had 
slightly better body composition, albeit not significantly (Table 5), and performed the function tests 
better (Table 6).  However, even in this subgroup of highly responsive patients, body composition 
(i.e. waist circumference, P = 0.039; waist:hip ratio, P < 0.001; ALM, P = 0.003; ALM%, P < 0.001; 
total FM, P = 0.014; BF%, P = 0.001; trunk FM, P = 0.017) and objectively-assessed function 
(relative deficits of 13 – 31%; IKES, P = 0.002; HGS, P < 0.001; STS-30, P < 0.001; 8’UG, P = 
0.008; 50’W, P = 0.014) were still much worse than for HC.   
 
DISCUSSION 
This is the first investigation of the effects on body composition and objectively-assessed physical 
function of current treatment regimens which aim to tightly control DA in RA patients. Overall the 
findings show that our T2T RA patients, including those who have achieved clinical remission, 
continue to have substantially reduced muscle mass, much greater levels of adiposity (especially in 
the trunk), and considerably worse function than sedentary age- and sex-matched healthy individuals. 
These adverse effects are despite a mean DAS28 of 2.8 (an ‘acceptable alternative therapeutic goal’ 
[23-24]) and achievement of ‘clinical remission’ in approximately half our patients, both of which 
indicate that our cohort is well-treated and generally benefiting from the T2T approach.   
 
Whilst the precise mechanisms underlying rheumatoid cachexia remain unclear, disease activity (i.e. 
inflammation) is widely accepted to be the primary driver [1, 13, 27, 29, 41]. Hence, it would be 
anticipated that the success of T2T in suppressing inflammation would be reflected in improved body 
composition in RA patients treated exclusively by this strategy relative to patients who received 
earlier, less clinically effective treatments.  However, the proportional loss of muscle mass of ~10 % 
observed in our current patients relative to matched, sedentary healthy controls is similar to what we 






























































had noted in stable, pre-T2T RA patients (~9%, for patients with a mean RA Disease Activity Index 
(RADAI) = 3.1 ± 0.3 [4]; and ~11%, for patients with RADAI = 2.65 ± 1.4 [3]).  This current deficit 
is also in line with the DXA-assessed ALM/BM% differences between controlled pre-T2T patients 
and healthy individuals described by others; i.e. 12% [5], 8% [42], 9% [43] (data collection 2004-
2006), 11% in women and 10% in men [2] (RA patients diagnosed 1995-2001) and in the follow-up 
to the last study, 11% in women and 7% in men [44].  Additionally, Elkan et al [7] (data collection 
2004-2005) found an 11% reduction in DXA-assessed fat free mass index (FFM/height (m)2) of RA 
patients with active disease (mean DAS28 = 5.5) versus a matched European reference population.   
 
The elevated adiposity we observed in our T2T RA patients relative to sedentary controls (FM (kg) 
increased by 26.5%, BF% increased 15.5%, trunk FM increased 32.3%) is also consistent with the 
observations made in our pre-T2T RA patients (total FM increases of ~17% [4] and ~13% [3] versus 
HC), and generally with the DXA-assessed disparities in adiposity reported by others in stable, pre-
T2T RA patients relative to matched HC (FM (kg) increased by 12% [5]; FM and trunk FM 
increased 13% and 25%, respectively [43]; FM and trunk FM increased 12.5% and 13.5%, 
respectively, in females, and 5.4% and 7.1% in males [42]; FM and trunk FM increased 13.5% and 
21.6%, respectively, in females, with no additional adiposity in males [2]; and FM and trunk FM 
increased 15.3% and 19.4%, respectively, in females, with no additional adiposity in males [44]). 
Whilst the RA patients in the current study were more sedentary than the HC, the between-group 
difference only amounted to approximately 30 minutes walking/week, and both groups, by a 
distance, failed to achieve the minimum recommendation for long-term loss of FM of 250 min/week 
of moderate intensity physical activity (PA) [45].  This 30 minute disparity in low-moderate intensity 
PA would also not account for the difference in MM, as higher-intensity exercise is required to elicit 
hypertrophy [45]. Thus, our findings clearly indicate that rheumatoid cachexia has not been resolved, 
or even attenuated, by tight control of DA, despite the other clinical benefits this approach confers. 































































We also demonstrated in this study that objectively-assessed physical function has not improved with 
T2T therapy.  This finding is not surprising in view of the lack of improvement in either muscle mass 
or fat mass, and the strong association between these and physical function in RA patients [16, 20-
22]. In our T2T patients, strength relative to health controls was reduced by ~25% and the 
performance level of tests designed to reflect the ability to perform ADL and live independently [38], 
reduced by about a third.  More tellingly with regard to the effect of T2T on function, the test scores 
obtained by patients in the current study were not better, and in some cases were worse (8’UG, 
50’W), than those of patients in our earlier studies [3-4, 9-12, 30-31] who were of similar age and 
gender distribution.  To provide a context of how poor the physical function of our T2T RA patients 
is, Rikli and Jones [38] recently published minimal fitness standards compatible with living 
independently until late in life using objective tests (including STS-30 and 8’UG).  In the present 
study, the RA women (mean age 58.6 years) achieved a STS-30 score appropriate for healthy 
‘moderate functioning’ women aged 80-84 years, and the RA men (mean age of 65.0 years) a score 
in line with healthy ‘moderate functioning’ men of 85-89 years. For the 8’UG test, the respective 
equivalents were 85-89 years for the women, and the men failed to achieve the standard of 90-94 
year old healthy men (the highest age category).  Hence, on average, both the female and male 
patients had the function of healthy individuals approximately 25 years older.   
 
Despite the substantial deficits in objectively-measured physical function (28-34% worse than 
sedentary HC), it is revealing that the patients generally rated their disability as only being ‘mild’ 
(mean MDHAQ = 0.57).  Also of interest, is that our earlier (pre-T2T) patients, although generally 
performing the objective tests as well, if not better than, the recent T2T patients, subjectively rated 
their disability as being higher (e.g. data collected 2005-2007, baseline means; DAS28 = 3.3, STS30 
= 12.5 reps, 50’W = 9.3 secs, IKES = 323 N, MDHAQ = 0.91 [9]).  This improvement in 






























































subjectively-assessed function (e.g. HAQ, MDHAQ) with T2T has been widely reported [26, 32-33] 
and may be due to reductions in pain [25], as pain is known to strongly influence HAQ scores [34-
35, 46]. This discord between objectively- and subjectively-assessed function in stable RA patients, 
together with the underestimation RA patients have of their disability, highlights the value of 
objective function tests and provides further evidence of their greater sensitivity for detecting 
functional change in patients with well-controlled disease [9, 36].  
 
A key aim of T2T is the “normalisation of function” (e.g. “Overarching principal” B; 
EULAR/International Task Force Recommendations [23-24]; ACR [28]). Our findings indicate that 
T2T has made inadequate progress in achieving this, even for patients achieving ‘remission’ (DAS28 
= 2.0 ± 0.4; whose performance of function tests was approximately 1/5th – 1/3rd poorer than 
sedentary HC). Additionally, we may have underestimated the extent of functional loss (and the 
perturbations in body composition) existing in broader RA populations as low DA and a high 
remission rate were achieved for our patients primarily with DMARD monotherapy, and no recourse 
to biologics, indicating that our cohort generally only has mild-moderate, and responsive, disease. 
 
Another point to raise is the failure of widely-used measures of treatment efficacy for T2T (e.g. 
DAS28) to assess function, either objectively or subjectively, which is counter to both the 
prominence that restoration of physical function has amongst the goals of this treatment, and the 
strong associations function has with morbidity, mortality, treatment costs and patient quality of life 
in RA [47]. 
 
An obvious question arising from our results is why has T2T failed to improve body composition 
and, consequently, physical function, given its beneficial effects on inflammation and disease 
activity, the purported drivers of rheumatoid cachexia?  A likely explanation is that the perturbations 






























































in body composition predominantly occur very early in the disease (i.e. during the ‘pre-clinical’ 
stage), and thus prior to the initiation of treatment. This proposal is consistent with: i) the absence of 
differences in anthropometric, body composition, or physical function measures between our ‘recent’ 
and ‘established’ RA patients; ii) reports of a similar incidence and magnitude of rheumatoid 
cachexia in recently diagnosed RA patients as for established patients [2, 12]; iii) indications that the 
rate of muscle loss in established, controlled patients is similar to that of healthy individuals [10, 44]; 
and iv) the consistent findings that disease processes, including inflammation and co-morbidity risk 
are already elevated in the pre-clinical period [48]. 
 
To summarise, our study shows that T2T, despite its enhanced efficacy in reducing DA, 
inflammation and joint damage, has not improved patients’ body composition or physical function 
relative to previous treatment regimes.  As a consequence, RA patients remain significantly muscle 
wasted and fatter, and this, at least in part, accounts for why they have substantially impaired 
function relative to healthy individuals.  Unfortunately, these important adverse consequences of RA 
are usually neglected as the T2T regimen posits that the DAS28 score should be the clinician’s 
primary concern.  Consequently, in this pharmacological model of treatment, focus on the need for 
rehabilitation has diminished.  The inclusion of an objective function test(s) during clinical reviews 
of disease activity would highlight to both the rheumatologist and the patient the need for adjunct 
treatments, such as high intensity exercise (especially resistance training [3, 9] and nutritional 
supplementation [11, 49-50], that specifically aim to restore body composition and physical function 
in RA patients.  
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TABLE 1. Demographic and clinical characteristics for rheumatoid arthritis patients and 
sedentary, age- and sex-matched health controls 
 RA (n = 82) HC (n = 85) P 
Age (years)  60.9 (±11.7) 60.9 (±8.1) 0.962 
Sex (n female) (%) 53 (65) 55 (65) 0.992 
Disease duration (months) 23.8 (±19.0) - - 
Seropositive RA; n (%) 67 (85) - - 
DAS28 (0-10) 2.8 (1.0) - - 
Medications, n (%) 
Methotrexate a 68 (83) - - 
Hydroxychloroquine 26 (32) - - 
Leflunomide 7 (9) - - 
Sulfasalazine 5 (6) - - 
Tacrolimus 3 (4) - - 
Mycophenolate mofetil 1 (1)   
Biologic  0 (0) - - 
Mono-DMARD therapy 48 (59)   
Combination DMARDs b 30 (37) - - 
No DMARD 3 (4)   
Corticosteroids c 7 (9) 1 (1) 0.026* 
Analgesics/NSAIDs 44 (54) 8 (9) < 0.001* 
Smoking status, n (%) 
Current smokers; n (%) 18 (22) 3 (5) < 0.001* 
Ex-smokers; n (%) 39 (48) 25 (31) < 0.016* 
Never smokers; n (%) 25 (30) 52 (61) < 0.001* 






























































Subjective measure of disability 
MDHAQ score (/3) 0.57 (±0.54) 0.08 (±0.24) 0.001* 
Exercise frequency
 d
, n (%)    
Exercise frequency score (0-3) 1.1 (±1.3) 2.2 (±1.0) < 0.001* 
Do not regularly exercise (0) 43 (52) 9 (11) < 0.001* 
1-2 times a month (1) 6 (8) 7 (8) 0.825 
1-2 times a week (2) 11 (14) 27 (32) 0.005* 
>3 times a week (3) 20 (25) 41 (49) 0.001* 
 
Unless stated, data presented as mean (±SD). Differences at baseline were assessed using analyses of 
variance or Chi-square test as appropriate. RA = rheumatoid arthritis; HC = healthy control group; 
Seropositive RA = rheumatoid factor and/or anti-CCP seropositive; DAS28 = Disease Activity Score 
in 28 joints; a = supplemented with folate; DMARD = disease modifying anti-rheumatic drug; b = 
double or triple DMARD therapy; c = current corticosteroid range 5.0 – 10.0 mg/d; NSAID = non-
steroidal anti-inflammatory drug; MDHAQ = multi-dimensional health assessment questionnaire; d = 
self-reported exercise frequency taken from MDHAQ (not reported: RA = 2, HC = 1); Exercise 
frequency score: 0 = no regular exercise; 1 = 1-2 times a month; 2 = 1-2 times a week; 3 = >3 times a 






































































TABLE 2. Body composition measures for rheumatoid arthritis patients and sedentary, age- 
and sex-matched health controls  
 
RA 
(n = 82) 
HC 
(n = 85) 
% difference  
 (CI for absolute 
difference) 
P 
Waist circ. (cm) 91.6 (±17.9) 83.9 (±10.8) ↑ 8.4 (3.2 – 12.2) 0.001* 
Hip circ. (cm) 101.9 (±12.7) 99.1 (±7.8) ↑ 2.7 (-0.4 – 6.1) 0.128 
Waist: hip ratio 0.90 (±0.10) 0.85 (±0.08) ↑ 5.6 (0.0 – 0.1) < 0.001* 
BM (kg) 





↑ 6.3 (0.2 – 9.3) 
↓ 3.0 (0.5 – 5.5) 
0.093# 
0.019* 
BMI (kg/m2) 28.0 (±6.0) 25.4 (±3.4) ↑ 9.3 (-4.1 - -1.2) 0.002* 
DXA-assessed measures 
ALM (kg) 19.8 (±4.6) 20.9 (±5.2) ↓ 5.6 (-0.4 – 2.6) 0.158 
ALM % (ALM/TBM %) 26.2 (±4.0) 28.8 (±4.2) ↓ 9.9 (1.4 – 3.9) < 0.001* 
Total LM (kg) 48.7 (±9.8) 49.5 (±10.0) ↓ 1.6 (-2.2 – 3.9) 0.578 
TLM % (LM/BM %) 64.4 (±7.5) 68.6 (±6.8) ↓ 6.5 (1.9 – 6.3) < 0.001* 
Total FM (kg) 25.8 (±10.4) 20.4 (±6.2) ↑ 26.5 (-7.9 - -2.7) < 0.001* 
BF% 32.7 (±7.8) 28.3 (±7.2) ↑ 15.5 (2.1 – 6.7) < 0.001* 
Trunk FM (kg) 13.1 (±6.3) 9.9 (±3.7) ↑ 32.3 (1.6 – 4.8) 0.001* 
Data presented as mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = 
healthy control group; BM = body mass; BMI = body mass index; DXA = dual energy x-ray 
absorptiometry; ALM = appendicular lean mass; TLM = total lean mass; FM = fat mass; BF% = % 
body fat (i.e. FM/BM x 100); unless adjusted by Bonferroni adjustment * = significant (P < 0.05), # 
= trend (P = 0.05 - 0.10). 






























































TABLE 3. Objective physical function and self-reported disability for rheumatoid arthritis 
patients and sedentary, age- and sex-matched health controls  
 RA  
(n = 82) 
HC 
(n = 85) 
Absolute difference 
(% difference) (CI) 
P 
IKES (N) 380 (±140) 472 (±152) ↓ 92 (24.3) (46 – 138) < 0.001* 
HGS (kg) 26.5 (±8.8) 33.2 (±9.9) ↓ 6.7 (25.3) (3.8 – 9.7) < 0.001* 
STS-30 test (reps) 12.0 (±3.6) 16.1 (±4.3) ↓ 4.1 (34.2) (2.8 – 5.3) < 0.001* 
8’UG (secs) 7.4 (±3.9) 5.1 (±1.0) ↑ 2.3 (31.1) (1.4 – 3.1) < 0.001* 
50’W (secs) 10.7 (±5.3) 7.7 (±1.8) ↑ 3.0 (28.0) (1.8 – 4.3) < 0.001* 
Data presented as mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = 
healthy control group; IKES = isometric knee extensor strength; HGS = handgrip strength; STS-30 = 
Sit-to-stands in 30 seconds; 8’UG = 8-foot up and go; 50’W = 50-foot walk: unless adjusted by 









































































TABLE 4. Demographic and clinical characteristics for rheumatoid arthritis patients in ‘remission’ (DAS28 < 2.6) or not (DAS28 ≥ 2.6) 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 ‘In remission’ (n = 40) ‘Not in remission’ (n = 42) P HC (n = 85) P 
Age (years)  60.4 (±12.2) 61.4 (±11.3) 0.706 60.9 (±8.1) 0.764 
Sex (n female) (%) 23 (58) 30 (71) 0.187 55 (65) 0.435 
Disease duration (months) 23.1 (±17.5) 24.5 (±20.6) 0.740 - - 
Serpositive RA; n (%) 32 (80) 35 (83) 0.886 - - 
DAS28 (0-10) 2.0 (±0.4) 3.6 (±0.8) < 0.001* - - 
CRP (mg/L) 7.3 (±7.7) 13.1 (±14.4) 0.024* - - 
Medications, n (%)   
Methotrexate a 34 (85) 34 (81) 0.626 - - 
Hydroxychloroquine 3 (8) 2 (5) 0.604 - - 
Leflunomide 3 (8) 4 (10) 0.743 - - 
Sulfasalazine 13 (33) 13 (31) 0.880 - - 
Tacrolimus 1 (3) 1 (2) 0.972 - - 
Mycophenolate mofetil 0 (0) 1 (2) - - - 
Biologic  0 (0) 0 (0) - - - 
Mono-DMARD therapy 24 (60) 25 (60) 0.930 - - 
Combination DMARDs b 15 (38) 15 (36) 0.930 - - 
No DMARD 1 (3) 2 (5) 0.586 - - 
Corticosteroids c 3 (8) 4 (10) 0.743 1 (1) 0.061* 
Analgesics/NSAIDs 16 (40) 28 (67) 0.015* 8 (9) < 0.001* 






























































Smoking status, n (%)      
Current smokers; n (%) 7 (18) 11 (26) 0.180 3 (5) 0.014* 
Ex-smokers; n (%) 19 (48) 20 (48) 0.493 25 (31) 0.007* 
Never smokers; n (%) 14 (35) 11 (26) 0.542 52 (61) 0.001* 
Subjective measure of disability 
MDHAQ score (/3) 0.32 (±0.32) 0.81 (±0.59) < 0.001* 0.08 (±0.04) 0.001* 
Exercise frequency
 d
, n (%)      
Exercise frequency score (0-3) 1.1 (±1.3) 1.2 (±1.3) 0.733 2.2 (±1.0) < 0.001* 
Do not exercise (0) 22 (55) 21 (50) 0.733 7 (8) < 0.001* 
1-2 times a month (1) 4 (10) 2 (5) 0.363 7 (8) 0.745 
1-2 times a week (2) 4 (10) 7 (18) 0.376 27 (32) 0.009* 
>3 times a week (3) 10 (25) 10 (25) 0.900 41 (49) 0.014* 
Unless stated, data presented as mean (±SD). Differences at baseline were assessed using analyses of variance or Chi-square test as appropriate. 
Seropositive RA = rheumatoid factor and/or anti-CCP seropositive; DAS28 = Disease Activity Score in 28 joints; a = supplemented with folate; 
DMARD = disease modifying anti-rheumatic drug; b = double or triple DMARD therapy; c = current corticosteroid range 5.0 – 10.0 mg/d; 
NSAID = non-steroidal anti-inflammatory drug; MDHAQ = multi-dimensional health assessment questionnaire; d = self-reported exercise 
frequency taken from MDHAQ (not reported: RA = 2, HC = 1); Exercise frequency score: 0 = no regular exercise; 1 = 1-2 times a month; 2 = 1-
2 times a week; 3 = >3 times a week; unless adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 0.05 - 0.10). 
 
 






























































TABLE 5. Body composition measures for rheumatoid arthritis patients in ‘remission’ (DAS28 < 2.6) or not (DAS28 ≥ 2.6) 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 ‘In remission’ 
(n = 40) 
‘Not in remission’ 










Waist circ. (cm) 90.3 (±16.5) 92.9 (±19.2) -2.6 (-10.5 – 5.3) 0.514 0.258 83.9 (±10.8) -6.4 (-10.7– - 0.3) 0.039* 
Hip circ. (cm) 100.0 (±10.0) 103.8 (±14.7) -3.9 (-9.4 – 1.7) 0.169 0.246 99.1 (±7.8) -0.9 (-5.1 – 2.9) 0.592 









-3.2 (-11.1 – 4.7) 







-3.2 (-7.3 – 2.9) 
2.1 (-1.1 – 5.2) 
0.397 
0.195 
BMI (kg/m2) 27.0 (±5.1) 29.0 (±6.7) -2.0 (-4.6 – 0.7) 0.143 0.133 25.4 (±3.4) -1.6 (-3.4 – 0.2) 0.084# 
DXA-assessed measures 
ALM (kg) 19.7 (±4.6) 19.9 (±4.6) -0.1 (-2.2 – 1.9) 0.905 0.148 20.9 (±5.2) 1.2 (0.6 – 2.8) 0.003* 
ALM % (ALM/TBM %) 26.9 (±3.9) 25.5 (±3.9) 1.3 (-0.4 – 3.1) 0.122 0.347 28.8 (±4.2) 1.9 (1.2 – 3.5) < 0.001* 
TLM (kg) 48.2 (±9.4) 49.2 (±10.3) -1.0 (-5.4 – 3.4) 0.650 0.071# 49.5 (±10.0) 1.3 (-0.2 – 4.6) 0.052# 
Total LM % (LM/TBM %) 65.5 (±6.6) 63.3 (±8.0) 2.2 (-1.0 – 5.5) 0.179 0.458 68.6 (±6.8) 3.1 (1.5 – 5.8) 0.001* 
Total FM (kg) 24.2 (±9.2) 27.3 (±11.3) -3.1 (-7.7 – 1.4) 0.176 0.241 20.4 (±6.2) -3.8 (-7.1 - -0.8) 0.014* 
BF% 31.5 (±7.0) 33.8 (±8.5) -2.4 (-5.8 – 1.0) 0.170 0.434 28.3 (±7.2) -3.2 (-6.1 - -1.5) 0.001* 
Trunk FM (kg) 12.2 (±6.1) 13.9 (±6.4) -1.6 (-4.4 – 1.1) 0.242 0.252 9.9 (±3.7) -2.3 (-4.3 - -0.4) 0.017* 
Data presented as unadjusted mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy controls; BM = body mass; 
BMI = body mass index; DXA = dual x-ray absorptiometry; ALM = appendicular lean mass; TLM = total lean mass; FM = fat mass; BF% = % 






























































body fat (i.e. FM/BM x 100); unless adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 0.05 - 0.10); P¥ = adjusted 











































































TABLE 6. Objective physical function and self-reported disability for rheumatoid arthritis in ‘remission’ (DAS28 < 2.6) or not (DAS28 
≥ 2.6) 
 ‘In remission’ vs ‘Not in remission’ HC vs ‘In remission’ 
 
‘In remission’ 
(n = 40) 
‘Not in 
remission’  










IKES (N) 414 (±141) 343 (±130) 71 (10 – 132) 0.023* 0.052# 477 (±155) 62 (26 - 117) 0.002* 
HGS (kg) 29.6 (±8.3) 22.9 (±9.3) 6.6 (2.7 – 10.5) 0.001* 0.002* 33.4 (±10.0) 3.8 (2.4 – 7.4) < 0.001* 
STS-30 test (reps) 12.3 (±3.3) 11.7 (±3.9) 0.5 (-1.1 – 2.1) 0.513 0.459 16.1 (±4.3) 3.8 (2.3 – 5.3) < 0.001* 
8’UG (secs) 6.6 (±2.1) 8.2 (±4.9) -1.6 (-3.3 – 0.1) 0.057# 0.042* 5.1 (±1.0) -1.5 (-2.5 - -0.4) 0.008* 
50’W (secs) 9.5 (±2.4) 11.9 (±6.8) -2.3 (-4.6 - - 0.1) 0.042* 0.037* 7.7 (±1.8) -1.8 (-3.3 - -0.4) 0.014* 
Data presented as unadjusted mean (±SD). CI = 95 % confidence interval; RA = rheumatoid arthritis; HC = healthy controls; IKES = isometric 
knee extensor strength; HGS = handgrip strength; STS-30 = Sit-to-stands in 30 seconds; 8’UG = 8-foot up and go; 50’W = 50-foot walk; unless 
adjusted by Bonferroni adjustment * = significant (P < 0.05); # = trend (P = 0.05 - 0.10); P¥ = adjusted significance value when sex included as 
co-variant due to a difference in the proportion of males to females.  
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